Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
CONCLUSION: The presence of the primary prostate tumor seems to play a detrimental role in mCRPC patients undergoing 223Ra treatment in absence of other concomitant anticancer therapy. On the other hand a previous RP might play a protective role.
PMID: 31601517 [PubMed - as supplied by publisher]
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Serretta V, Valerio MR, Costa R, Tripoli V, Morabito A, Princiotta A, Scalici Gesolfo C, Borsellino N, Verderame F, Gebbia V, Licari M, Sanfilippo C, members of the GSTU Foundation Tags: Urol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Hematology | Hormones | Prostate Cancer | Prostatectomy | Statistics | Study | Toxicology | Urology & Nephrology